Our Philadelphia Janumet drug injury lawyers are evaluating cases from people who have developed pancreatic cancer and other serious injuries from the drug Janumet. Janumet is a type-2 diabetes medication manufactured by Merck & Co. that is associated with serious injuries and death. Dangerous Janumet side effects may include:
- pancreatitis (both hemorrhagic and necrotizing)
- pancreatic cancer
- thyroid cancer
- kidney failure
- wrongful death
Janumet and Pancreatic Cancer
Janumet is a combination of metformin (a type-2 diabetes treatment drug) and the incretin therapy drug Januvia.* Janumet and Januvia are dipeptidyl peptidase-4 (DPP-4) inhibitors, which affect the level of incretin hormones in a patient’s bloodstream to reduce blood sugar following a meal. The drug’s action on glucagonlike peptide 1 (GLP-1) receptor activity has been associated with an increased risk of pancreatic cancer.
Additional incretin therapy and incretin mimetic drugs include:
- Onglyza (see Philadelphia Onglyza Drug Injury Lawyers)
- Januvia (see Philadelphia Januvia Drug Injury Lawyers)
- Victoza (see Philadelphia Victoza Drug Injury Lawyers)
- Byetta (see Philadelphia Byetta Drug Injury Lawyers)
- Bydureon (see Philadelphia Bydureon Drug Injury Lawyers)
- Janumet XR
Incretin Therapy Warnings and Studies
Study results reported in a July 2011 issue of Gastroenterology revealed a six-fold increase in risk of pancreatitis and an increased risk of pancreatic cancer with incretin therapy. Drugs included in the study were dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide 1 (GLP-1) receptor agonists.
The U.S. Food and Drug Administration (FDA) released a drug safety communication on March 14, 2013, advising of a potential increase in risk of pancreatitis and pancreatic duct metaplasia following use of Janumet and other incretin therapies.
An April 8, 2013, report by the National Institutes of Health (NIH) showed study results demonstrating a significantly increased risk of acute pancreatitis in users of incretin therapy drugs such as Janumet. Individuals studied exhibited a 40% larger than normal pancreas size.
The FDA reported a potential increased risk of rhabdomyolysis from use of Janumet and other incretin mimetic / therapy drugs after receipt of adverse event reports between April and June 2017.
Lawsuits filed by Philadelphia Janumet drug injury lawyers may allege that Janumet manufacturer Merck & Co.:
- produced and sold an unreasonably dangerous and defective drug
- failed to conduct sufficient pre-market testing of Janumet side effects before releasing it to the market
- failed to adequately warn physicians and consumers of the serious risks of pancreatic cancer and other dangerous side effects associated with Janumet
- engaged in false and aggressive advertising of Janumet despite knowledge of pancreatic cancer risks and risks of other dangerous side effects
Contact our Philadelphia Janumet Drug Injury Lawyers
Type-2 diabetes patients who developed serious injuries, including pancreatic cancer, from use of Janumet may be entitled to compensation from the manufacturer. Contact our Philadelphia Janumet drug injury lawyers, today, to inquire about filing a Janumet lawsuit.
*For additional information about Januvia injuries and lawsuits, see Philadelphia Januvia Drug Injury Lawyers.